公开(公告)号：US20240076289A1

公开(公告)日：2024-03-07

申请号：US18450586

申请日：2023-08-16

Applicant: Scorpion Therapeutics, Inc.

Inventor： David St. Jean, JR.

IPC: C07D405/12

CPC classification number: C07D405/12

Abstract: This disclosure provides compounds of Formula (I), Formula (II), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Kα). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) PI3Kα activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

公开(公告)号：US12084434B2

公开(公告)日：2024-09-10

申请号：US18509967

申请日：2023-11-15

Applicant: Scorpion Therapeutics, Inc.

Inventor： David St. Jean, Jr.

IPC: C07D405/12

CPC classification number: C07D405/12

Abstract: This disclosure provides compounds of Formula (I), Formula (II), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Kα). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) PI3Kα activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

公开(公告)号：US20240158376A1

公开(公告)日：2024-05-16

申请号：US18509967

申请日：2023-11-15

Applicant: Scorpion Therapeutics, Inc.

Inventor： David St. Jean, JR.

IPC: C07D405/12

CPC classification number: C07D405/12

Abstract: This disclosure provides compounds of Formula (I), Formula (II), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Kα). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) PI3Kα activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

公开(公告)号：US11897871B1

公开(公告)日：2024-02-13

申请号：US18450586

申请日：2023-08-16

Applicant: Scorpion Therapeutics, Inc.

Inventor： David St. Jean, Jr.

IPC: C07D405/12

CPC classification number: C07D405/12

Abstract: This disclosure provides compounds of Formula (I), Formula (II), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Kα). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) PI3Kα activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

公开(公告)号：US20240101576A1

公开(公告)日：2024-03-28

申请号：US18030211

申请日：2021-10-08

Applicant: Scorpion Therapeutics, Inc.

Inventor： Angel Guzman-Perez ,  Benjamin C. Milgram ,  Ryan D. White ,  David St. Jean, JR.

IPC: C07D519/00 ,  A61K45/06 ,  C07D471/04 ,  C07D471/20 ,  C07D491/20 ,  G01N33/574

CPC classification number: C07D519/00 ,  A61K45/06 ,  C07D471/04 ,  C07D471/20 ,  C07D491/20 ,  G01N33/57415 ,  G01N2333/485 ,  G01N2440/14

Abstract: This disclosure provides chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit epidermal growth factor receptor (EGFR, ERBB 1) and/or Human epidermal growth factor receptor 2 (HER2, ERBB2). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) EGFR and/or HER2 activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

公开(公告)号：US20240300939A1

公开(公告)日：2024-09-12

申请号：US18568899

申请日：2022-06-13

Applicant: Scorpion Therapeutics, Inc.

Inventor： David St. Jean, Jr. ,  Maxwell David Cummings

IPC: C07D417/12 ,  A61K31/343 ,  A61K31/381 ,  A61K31/382 ,  A61K31/4035 ,  A61K31/416 ,  A61K31/427 ,  A61K31/437 ,  A61K31/443 ,  A61K31/4525 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  C07D307/81 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/107 ,  C07D498/10

CPC classification number: C07D417/12 ,  A61K31/343 ,  A61K31/381 ,  A61K31/382 ,  A61K31/4035 ,  A61K31/416 ,  A61K31/427 ,  A61K31/437 ,  A61K31/443 ,  A61K31/4525 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  C07D307/81 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/107 ,  C07D498/10

Abstract: This disclosure provides compounds of Formula (I), Formula (II), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Ka). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) PI3Ka activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

公开(公告)号：US20240400543A1

公开(公告)日：2024-12-05

申请号：US18795384

申请日：2024-08-06

Applicant: Scorpion Therapeutics, Inc.

Inventor： David St. Jean, Jr.

IPC: C07D405/12

Abstract: This disclosure provides compounds of Formula (I), Formula (II), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Kα). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) PI3Kα activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

公开(公告)号：US20240343728A1

公开(公告)日：2024-10-17

申请号：US18293823

申请日：2022-08-08

Applicant: Scorpion Therapeutics, Inc.

Inventor： David St. Jean, JR.

IPC: C07D473/32 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/52 ,  C07D405/12 ,  C07D471/04

CPC classification number: C07D473/32 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/52 ,  C07D405/12 ,  C07D471/04

Abstract: This disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Kα). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) PI3Kα activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

公开(公告)号：US20230364070A1

公开(公告)日：2023-11-16

申请号：US18027316

申请日：2021-09-22

Applicant: Scorpion Therapeutics, Inc.

Inventor： Benjamin C. Milgram ,  Ryan D. White ,  David St. Jean, Jr. ,  Angel Guzman-Perez

IPC: A61K31/444 ,  C07D471/04 ,  C07D519/00 ,  C07D471/20 ,  A61K31/506 ,  A61K31/5377 ,  A61K39/395 ,  A61K31/517 ,  A61K31/4706

CPC classification number: A61K31/444 ,  C07D471/04 ,  C07D519/00 ,  C07D471/20 ,  A61K31/506 ,  A61K31/5377 ,  A61K39/3955 ,  A61K31/517 ,  A61K31/4706

Abstract: This disclosure provides chemical entities of Formula (I) (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit epidermal growth factor receptor (EGFR, ERBB 1) and/or Human epidermal growth factor receptor 2 (HER2, ERBB2). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) EGFR and/or HER2 activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.